Biology Reference
In-Depth Information
Pakker NG, Roos MTL, van Leeeuwen R. 1997. Patterns of T cell repopulation, viral load reduc-
tion, and restoration of T cell function in HIV-infected persons during therapy with di¨erent
antiretroviral agents. J AIDS Hum Retroviruses 16: 318±326.
Pakker NG, Nottermans DW, de Boer RJ, et al. 1998. Biphasic kinetics of peripheral blood T cells
after triple combination therapy in HIV-1 disease. Lancet 351: 1682±1686.
Pantaleo G, Graziosi C, Demarest L, et al. 1993. HIV infection is active and progressive in lym-
phoide tissues during the clinically latent stage of the disease. Nature 362: 355±360.
Papiernik M, de Moraes ML, Pontoux C, Vasseur F, Penit C. 1998. Regulatory CD4 T cells: ex-
pression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency. Int Immunol
10: 371±378.
Poignard P, Sabbe R, Picchio GR, et al. 1999. Neutralizing antibodies have limited e¨ects on the
control of established HIV-1 infection in vivo. Immunity 10: 431±438.
Pontesilli O, Grade-Kerkhof S, Noterman FW, et al. 1999. Functional T cell reconstitution and
HIV-1-speci®c cell-mediated immunity duting highly active antiretroviral therapy. J Infect Dis
180: 76±85.
Prince HE, Kermani-Arab B, Fahey JL. 1984. Deprest interleukine-2 receptor expression in ac-
quired immunode®ciency and lymphadenopathy syndromes. J Immunol 133: 1313±1317.
Richman DD. 1996. HIV therapeutics. Science 272: 1886±1891.
Rizzardi GP, Barcellini W, Tambussi G, Lillo F. 1996. Plasma levels of soluble CD30, tumour
necrosis factor (TNF)-alpha and TNF receptors during primary HIV-1 infectionÐcorrelation
with HIV-1 RNA and the clinical outcome. AIDS 10: F45±F50.
Roeder M, Dubs JG, Anderson MT. 1995. CD8 naive T cell counts decrease progressively in HIV-
infected adults. J Clin Invest 95: 2061±2065.
Romagnani S. 1996. TH1 and TH2 in human diseases. Clin Immunol Immunopathol 80: 225±
235.
Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. 1998. Flexible programs of chemokine receptor
expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 187: 875±883.
Shearer GM. 1998. HIV-induced immunopathogenesis. Immunity 9: 587±593.
Shimizu Y, Yamazaki S, Sakaguchi S. 1999. Induction of tumor immunity by removing
CD25
CD4
T cells: a common basis between tumor immunity and autoimmunity. J Immunol
163: 5211±5218.
Sloand EM, Young NS, Kumar P, et al. 1997. Role of Fas ligand ad receptor in the mechanism of T
cell depletion in aquired immunode®ciency syndrome: e¨ect on CD4
lymphocyte depletion and
human immunode®ciency virus replication. Blood 89: 1357±1363.
Spina CA, Prince HE, Richman DD. 1997. Preferential replication of HIV 1 in the CD45RO
memory cell subset of primary CD4 lymphocytes in vitro. J Clin Invest 99: 1774±1785.
Sprent J. 1994. T and B memory cells. Cell 76: 315±322.
Suda T, Takahashi T, Golstein P, et al. 1993. Molecular cloning and expression of the Fas ligand, a
novel member of the tumor necrosis factor family. Cell 75: 1169±1178.
Thornton AM, Shevac, EM. 1998. CD4
CD25
immunoragulatory T cells suppress polyclonal T
cell activation by inhibiting IL-2 production. J Exp Med 188: 287±295.
Thornton AM, Shevac EM. 2000. Suppressor e¨ector function of CD4
CD25
immunoragulatory
T cells is antigen nonspeci®c. J Immunol 164: 183±190.
Trimble LA, Lieberman J. 1998. Circulating CD8 T lymphocytes in human immunode®ciency
virus-infected individuals have impaired function and downmodulate CD3 zeta, the signaling
chain of the T-cell receptor complex. Blood 91: 585±594.
Vigano A, Saresella M, Rusconi S, et al. 1998. Expression of CD38 on CD8 T cells predicts main-
tenance of high viraemia in HAART-treated HIV-1-infected children. Highly active anti-
retrouiral therapy. M lancet 352: 1905±1906.
